Search results for " bladder cancer"

showing 10 items of 50 documents

Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy f…

2020

Background: A marker of urothelial damage could be helpful for early detection and monitoring of local toxicity due to intravesical therapy for non-muscle invasive bladder cancer (NMIBC). The aim of the study was to investigate the correlation between fibronectin (FN) gene expression in bladder washings and local toxicity secondary to adjuvant intravesical therapy. Materials and methods: Patients undergoing adjuvant intravesical therapy for NMIBC and age-matched healthy patients were enrolled. Real time polymerase chain reaction was performed to analyze FN expression in bladder washings. Local toxicity was classified as: 0–1 mild (no medical therapy), 2 moderate (medical therapy and/or inst…

Urologymedicine.medical_treatment030232 urology & nephrologyEarly detectionBacillus Calmette–Guerinlcsh:RC870-92303 medical and health sciences0302 clinical medicinefibronectinnon-muscle invasive bladder cancerGene expressionbladder washingMedicineBladder cancerbiologybusiness.industrytoxicitylcsh:Diseases of the genitourinary system. Urologymedicine.diseaseFibronectin030220 oncology & carcinogenesisToxicitybiology.proteinCancer researchBiomarker (medicine)biomarkerOriginal ArticlebusinessNon muscle invasiveAdjuvantTherapeutic advances in urology
researchProduct

Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study.

2011

Objectives: Nomograms are statistical models designed to maximize predictive accuracy. We have tested the statistical correlation between the predictions of International Bladder Cancer Nomogram Consortium and the clinical outcomes in a multicenter Italian cohort of patients treated with radical cystectomy (RC) and pelvic lymph-nodes dissection. Methods and materials: Two hundred four patients who underwent RC were selected for multiple variable and then enrolled in the study. Patients were tested by the "online tool" based on the nomogram, then stratified and risk grouped for 5-year predicted disease-free survival (pDFS): low risk (67%-100%), intermediate risk (34%-66%), and high risk grou…

Malemedicine.medical_treatmentKaplan-Meier EstimatePostoperative nomogramNomogramCohort StudiesRetrospective StudieArea under curvePostoperative Periodinvasive bladder cancer; Postoperative nomogramAged 80 and overSettore MED/24 - UROLOGIAinvasive bladder cancerMiddle AgedPrognosisOncologyArea Under CurveUrinary Bladder NeoplasmCohortFemaleHumanCohort studyAdultmedicine.medical_specialtyPrognosiUrologyUrologyCystectomyDisease-Free SurvivalCystectomymedicineHumansAgedNeoplasm StagingRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryRetrospective cohort studyNomogrammedicine.diseaseRadical cystectomyNomogramsROC CurveUrinary Bladder NeoplasmsCohort StudieNeoplasm GradingPredictionbusinessStatistical correlationUrologic oncology
researchProduct

Second-Line Chemotherapy in Advanced Bladder Cancer

2000

MaleOncologyCarcinoma Transitional Cellmedicine.medical_specialtyClinical Trials Phase I as Topicbusiness.industryUrologyMiddle AgedGenes p53VinblastineSecond line chemotherapyClinical Trials Phase II as TopicMethotrexateUrinary Bladder NeoplasmsDoxorubicinInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAdvanced bladder cancerHumansMedicineFemaleCisplatinbusinessAgedUrologia Internationalis
researchProduct

PATIENT’S COMPLIANCE TO BCG. DO WE ADEQUATELY CONSIDER IT?

2014

Introduction: Several studies and meta-analysis demonstrated that BCG is the best treatment for conservative management of high-risk NMI-BC with a net benefit in terms of both recurrence-free and progression-free survival (1, 2). Maintenance lasting minimum one year is recommended. In spite of the effectiveness, the amount of patients who complete the manteinance schedule does not exceed 50% (3). The reasons of BCG maintenance interruption remain still unclear. The aim of our study was to investigate the causes of low adherence to 1-year full dose maintenance BCG in a large series. Patients and Methods: The clinical files of consecutive patients affected by T1 HG NMI-BC and undergoing adjuv…

BCG intravesical therapy bladder cancerSettore MED/24 - Urologia
researchProduct

Predictive value of positive NMP22 in patients with negative cytology and cystoscopy.

2010

NMP22 bladder cancer cytologySettore MED/24 - Urologia
researchProduct

LOCAL MICROWAVE HYPERTHERMIA AND INTRAVESICAL CHEMOTHERAPY AS BLADDER SPARING TREATMENT FOR SELECT MULTIFOCAL AND UNRESECTABLE SUPERFICIAL BLADDER TU…

1998

Purpose: The role of a combined regimen of local hyperthermia and topical chemotherapy in patients with multifocal and recurrent superficial bladder tumors not curable by transurethral resection was evaluated in a neodjuvant organ sparing clinical study. Materials and Methods: A total of 19 patients with multifocal, superficial grades 1 to 3 bladder tumors that recurred after intravesical chemoprophylaxis or immunoprophylaxis underwent local combined administration of microwave induced hyperthermia and intravesical chemotherapy as a debulking approach. Due to extensive superficial involvement of the bladder walls complete transurethral resection of all tumors seemed technically unfeasible i…

HyperthermiaAdultMalemedicine.medical_specialtymedicine.medical_treatmentUrologyAntineoplastic AgentsCystectomyBladder NeoplasmmedicineHumansMicrowavesAgedAged 80 and overChemotherapyCarcinoma Transitional CellUrinary bladderbusiness.industryintravesical chemotherapy bladder cancer microwave hyperthermiaHyperthermia InducedMiddle Agedmedicine.diseaseDebulkingSurgeryRegimenmedicine.anatomical_structureAdministration IntravesicalUrinary Bladder NeoplasmsChemoprophylaxisFeasibility StudiesFemaleNeoplasm Recurrence LocalbusinessThe Journal of Urology
researchProduct

Intravesical gemcitabine in superficial bladder tumors. Results of a phase I-II study

2004

the good tolerability of intravesical gemcitabine have been recently published. The evaluation of the activity on a papillary marker lesion is the best tool to measure the efficacy of a drug by intravesical route against superficial transitional cell carcinoma of the bladder (TCCB). The scientific background and the ethical acceptability of this approach have been validated by the European Organization for Research and Treatment of Cancer Urological Group. The aim of the present study was to evaluate the ablative efficacy of weekly intravesical instillations of gemcitabine against a histologically proven papillary marker lesion. MATERIAL & METHODS: Twenty-seven patients, affected by recurre…

Sperfial bladder cancer intravesical chemotherapy marker lesion gemcitabineSettore MED/24 - Urologia
researchProduct

Superficial Bladder Cancer Therapy: A Review

2005

Most bladder cancers present as a superficial disease, confined to the bladder mucosa or submucosal layer, without muscle invasion. Most superficial tumors have a propensity for recurrence after transurethral resection; some have a high risk for progression to muscle invasion. The treatment aim in superficial bladder cancer with intravesical therapy is three-fold: (1) eradicate existing disease, (2) prevention of recurrence, (3) prevention of tumor progression. The prognostic factors (tumor stage, grade, size, number and recurrence pattern) allow the stratification of tumors in different risk groups to plan treatment. Studies on pharmacokinetics have proved the efficacy of optimized drug de…

medicine.medical_specialtybusiness.industryUrologymedicineSuperficial bladder cancerGeneral MedicinebusinessUrologia Journal
researchProduct

FIBRONECTIN (FN) AND UROTHELIAL DAMAGE SECONDARY TO ADJUVANT INTRAVESICAL THERAPY

2014

Introduction and Objectives: Intravesical chemotherapy has been proven effective in preventing recurrence of low-risk non-muscle invasive bladder cancer (NMIBC). BCG is recognised as the best conservative treatment for intermediate and high risk NMIBC. Maintenance for at least one year is required to ameliorate the efficacy of adjuvant therapy. Discomfort and toxicity often cause interruption of adjuvant therapy, BCG particularly. Almost 50% of the patients undergoing BCG does not complete one year. A biomarker of urothelium damage would be helpful for timely detection of toxicity in order to ameliorate patient’s tolerance and compliance. The aim of the present study was to evaluate the gen…

Fibronectin bladder cancer toxicity intravesical chemotherapySettore MED/24 - Urologia
researchProduct

Environmental Risk Factors in Superficial Bladder Cancer

2004

As a preliminary approach to define the object of larger case-control studies, the distribution of potential risk factors coming from environmental pollution among patients affected by superficial bladder cancer (TCCB) has been analyzed. Material e Methods. The analysis included only patients affected by medium risk superficial TCCB. Forty Italian urological centres joined the study. Detailed information about age, sex, residency, employment, active and passive cigarette smoking, water resource, hair-dye use were centralized. All patients underwent TUR and early intravesical chemotherapy. The distribution of the above mentioned environmental factors was related to tumor characteristics suc…

PollutionPotential riskbusiness.industrymedia_common.quotation_subjectDistribution (economics)Water supplyEnvironmental pollutionGeneral MedicineEnvironmental riskEnvironmental healthSuperficial bladder cancerEnvironmental sciencebusinessmedia_commonUrologia Journal
researchProduct